Breaking News
Get 45% Off 0
Selloff or market correction? Either way, here's what to do next
See Overvalued Stocks

Biotech Stock Roundup: NVAX, CANF Up On Coronavirus Treatment Updates & More

By Zacks Investment ResearchStock MarketsMar 10, 2020 11:06PM ET
www.investing.com/analysis/biotech-stock-roundup-nvax-canf-up-on-coronavirus-treatment-updates--more-200515199
Biotech Stock Roundup: NVAX, CANF Up On Coronavirus Treatment Updates & More
By Zacks Investment Research   |  Mar 10, 2020 11:06PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
 
GILD
-1.08%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NVAX
-2.41%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AIM
+0.83%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MESO
-4.54%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
CANF
-6.98%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
KALA
-1.00%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

This week, the biotech sector was in focus with updates from biotechs evaluating their pipeline drugs and vaccines for the treatment of COVID-19. A new strain of coronavirus, which first appeared in late 2019 in China, has become a raging pandemic. This disease has been named COVID-19 and causes severe pneumonia-like symptoms in infected patients.

Recap of the Week’s Most Important Stories:

Novavax Surges on Funding for COVID-19 Vaccine: Shares of late-stage biotechnology company, Novavax, Inc. (NASDAQ:NVAX) , surged after it announced that the Coalition for Epidemic Preparedness (CEPI) awarded an initial funding of $4 million to support its efforts to develop a COVID-19 vaccine. CEPI and Novavax are in discussions regarding additional funding from CEPI to address the costs through the phase I.

Novavax is currently evaluating multiple recombinant nanoparticle vaccine candidates in animal models prior to advancing to clinical trials. The phase I is expected to start in late spring 2020. Novavax’s COVID-19 vaccine candidates were created with its proprietary recombinant protein nanoparticle technology platform to generate antigens derived from the coronavirus spike (S) protein. The company also expects to utilize its proprietary Matrix-M adjuvant with its COVID-19 vaccine candidates to enhance immune responses. Coronaviruses are a large family of viruses that spread from animals to humans and include diseases such as Middle East Respiratory Syndrome (MERS) and SARS, in addition to COVID-19.

Mesoblast Surges on News of Coronavirus Study: Mesoblast Limited (NASDAQ:MESO) announced plans to evaluate its allogeneic mesenchymal stem cell (MSC) product candidate, remestemcel-L, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19) in the United States, Australia, China and Europe. Shares soared on the news. Mesoblast is actively discussing with various government and regulatory authorities, medical institutions and pharmaceutical companies to implement these activities. Remestemcel-L is currently being studied in numerous clinical trials across several inflammatory conditions in elderly patients with lung disease and adults and children with steroid-refractory acute graft versus host disease.

Can-Fite to Evaluate RA Drug for Coronavirus: Can-Fite BioPharma Ltd. (NYSE:CANF) is exploring a collaboration to evaluate the effect of lead candidate, piclidenoson, against coronavirus. Piclidenoson, a novel, first-in-class, A3 adenosine receptor agonist (A3AR), is currently in phase III studies for rheumatoid arthritis (RA) and psoriasis. Data from the interim analysis of the phase III study will be released during the fourth quarter of 2020. This move is driven by reports of RA drugs being introduced for the treatment of coronavirus. Shares of the company rallied significantly on this news. Can-Fite’s drug candidates possess anti-viral effect protected by a U.S. patent, US7589075.

Gilead Announces Positive Data on Descovy: Gilead Sciences, Inc. (NASDAQ:GILD) announced positive long-term results from the DISCOVER study on Descovy for pre-exposure prophylaxis (PrEP). These longer-term efficacy and safety outcomes from the DISCOVER study showed that Descovy is effective for HIV prevention with non-inferior efficacy to Truvada and the drug has an improved bone and renal safety profile compared with Truvada at week 96. Meanwhile, a separate analysis of the DISCOVER study demonstrated that Descovy and Truvada were effective and well tolerated in Black and Hispanic/Latinx participants.

AIM ImmunoTech Drug Being Tested for COVID-19: AIM ImmunoTech (NYSE:AIM) announced that the National Institute of Infectious Diseases (NIID) in Japan will begin testing its drug, Ampligen, as a potential treatment for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The experimental program will be conducted at both the NIID and the University of Tokyo.

Kala Announces Data on Dry Eye Disease Drug: Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced positive top-line results from a late-stage study, STRIDE 3. The study is evaluating KPI-121 0.25%, which Kala plans to commercialize under the brand name EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25%, for the treatment of dry eye disease. STRIDE 3 met both of its primary efficacy endpoints, demonstrating a statistically significant improvement in the symptom endpoint of ocular discomfort severity at day 15 in the overall intent-to-treat (ITT) population and the predefined subgroup of ITT patients with more severe ocular discomfort at baseline.

Kala currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Performance

The Nasdaq Biotechnology index lost 3.41% in the last five trading sessions. Among the biotech giants, Regeneron gained 2.92% during this period. Over the past six months, shares of Regeneron have gained 67.43%. (See the last biotech stock roundup here: Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More)

What's Next in Biotech?

Stay tuned for more pipeline updates with a focus on treatments for the novel COVID-19.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>



Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Novavax, Inc. (NVAX): Free Stock Analysis Report

Can-Fite Biopharma Ltd (CANF): Free Stock Analysis Report

Hemispherx BioPharma, Inc. (AIM): Free Stock Analysis Report

Mesoblast Limited (MESO): Free Stock Analysis Report

Kala Pharmaceuticals, Inc. (KALA): Free Stock Analysis Report

Original post

Zacks Investment Research

Biotech Stock Roundup: NVAX, CANF Up On Coronavirus Treatment Updates & More
 

Related Articles

Dr. Arnout ter Schure
Is the S&P 500 Road to 6400-6500 in Jeopardy? By Dr. Arnout ter Schure - Mar 04, 2025 2

Using the Elliott Wave Principle (EWP), we have been successfully tracking the most likely path forward for the S&P 500 (SPX) over several months. Although there are many ways...

Biotech Stock Roundup: NVAX, CANF Up On Coronavirus Treatment Updates & More

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email